ReportLinker logo.jpg
Migraine Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)
February 20, 2020 13:33 ET | ReportLinker
New York, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Migraine Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)" -...
22157.jpg
Global Pain Therapeutics Market Report 2019: Market Trends & R&D Insights 2017-2023
February 20, 2019 06:55 ET | Research and Markets
Dublin, Feb. 20, 2019 (GLOBE NEWSWIRE) -- The "The Global Pain Therapeutics Market, 6th Edition: Market Trends & R&D Insights" report has been added to ResearchAndMarkets.com's ...
Pernix Therapeutics, Inc. logo
Pernix® Therapeutics Reports Third Quarter 2018 Financial Results
November 08, 2018 16:01 ET | Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced today its financial results for the three and nine...
Pernix Therapeutics, Inc. logo
Pernix Therapeutics Reports Second Quarter 2018 Financial Results
August 09, 2018 16:01 ET | Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced today its financial results for the three and...
Pernix Therapeutics, Inc. logo
Pernix Therapeutics Reports First Quarter 2018 Financial Results
May 10, 2018 16:01 ET | Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today its financial results for the three months...
Pernix Therapeutics, Inc. logo
Pernix Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
March 08, 2018 16:01 ET | Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., March 08, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today financial results for the three and twelve...
Pernix Therapeutics, Inc. logo
Pernix Therapeutics Announces Launch of Authorized Generic Version of Treximet® by Company’s Subsidiary, Macoven Pharmaceuticals
February 16, 2018 16:01 ET | Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced the launch of an authorized generic version...
Pernix Therapeutics, Inc. logo
Pernix Announces Reorganization of Sales Force to Focus on Zohydro® ER with BeadTek™ and Silenor®
January 05, 2018 08:30 ET | Pernix Therapeutics Holdings, Inc.
Anticipated Cost Savings of $7-$8 Million MORRISTOWN, N.J., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced...
Pernix Therapeutics, Inc. logo
Pernix Therapeutics Reports Third Quarter 2017 Financial Results
November 07, 2017 16:01 ET | Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, announced today financial results...
Pernix Therapeutics, Inc. logo
Pernix Therapeutics Announces Planned Departure of Chief Financial Officer
October 17, 2017 16:05 ET | Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced that Graham Miao,...